Eric Huang

Partner
Delos Capital
​​

Dr. Eric Huang

Dr. Eric Huang, Partner at Delos Capital since April 2024, brings over two decades of biotechnology expertise, highlighted by his transformative 12-year tenure at Moderna.

Career Highlights
Moderna (2012-2024)

General Manager and CSO, Moderna Genomics

Integrated mRNA technology with gene editing and genetics research

Pioneered next-generation genomic medicines

Founding CSO, Moderna's New Venture Labs (NVL)

Led industry-first in-house incubator

Conceived the mRNA vaccine platform, crucial for COVID-19 vaccine development

Recipient of the 2023 Warren Alpert Foundation Prize

Founding CSO, Autoimmune Therapeutic Area

Developed strategic portfolio and robust product pipeline

Advanced drug candidates from preclinical to IND stages

Launched Moderna's personalized cancer vaccine platform
Early Career

Business and corporate development roles at 

Seaside Therapeutics, 

Stromedix

Domantis

Education

Ph.D., Molecular and Medical Parasitology, New York University

MBA, Boston University

B.S., Emory University

A.A., Bard College at Simon's Rock
⠀Expertise and Focus

Dr. Huang excels in synthesizing knowledge across diverse fields, applying a mechanism-based approach to complex challenges in biotechnology and medicine. At Delos Capital, he leverages his extensive experience to identify and nurture innovative biotechnology ventures, bridging scientific discovery with commercial success.

 

Speech title & Synopsis

The mRNA Equation: Balancing Promise and Practical Constraints

.